1994
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisRemission InductionSurvival RateVincristineConceptsAdvanced stage diseaseProMACE-MOPPProMACE-CytaBOMBurkitt's lymphomaLocalized diseaseComplete responseInvolved-field radiation therapyCombination chemotherapy programsOverall survival rateEfficacy of cyclophosphamideTreatment of patientsHigh-grade lymphomaMedian followComplete remissionIntercurrent illnessAdult patientsChemotherapy programCombination chemotherapyOverall survivalAggressive lymphomaRadiation therapyPatientsLymphomaSurvival rateDisease
1991
The calculation of actual or received dose intensity: a comparison of published methods.
Longo D, Duffey P, DeVita V, Wesley M, Hubbard S, Young R. The calculation of actual or received dose intensity: a comparison of published methods. Journal Of Clinical Oncology 1991, 9: 2042-51. PMID: 1941063, DOI: 10.1200/jco.1991.9.11.2042.Peer-Reviewed Original ResearchConceptsSouthwest Oncology GroupTreatment courseEntire treatment coursePatient's treatment coursePrognostic factorsTreatment outcomesAggressive histology lymphomaCombination chemotherapy programsClinical prognostic factorsNational Cancer Institute studyDistinct patient populationsDose-related variablesDose intensityOncology GroupChemotherapy programPrognostic significancePatient populationStudy populationInstitute studyOutcomesRecent reportsEntire populationPopulationCourseDI data
1989
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
Longo D, Glatstein E, Duffey P, Ihde D, Hubbard S, Fisher R, Jaffe E, Gilliom M, Young R, DeVita V. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. Journal Of Clinical Oncology 1989, 7: 1295-302. PMID: 2788716, DOI: 10.1200/jco.1989.7.9.1295.Peer-Reviewed Original ResearchConceptsInvolved field radiation therapyRadiation therapyComplete remissionAggressive lymphomaCoronary artery bypass surgeryInvolved-field radiation therapyEarly hematogenous disseminationLocalized aggressive lymphomaTreatment-related deathsClinical stage IHigh-dose methotrexateArtery bypass surgeryCombination chemotherapy programsCycles of treatmentMedian followAggressive histologyBypass surgeryLeucovorin rescueChemotherapy programCombination chemotherapyHospital admissionLocal therapyHematogenous disseminationEffective treatmentLymphoma histology
1988
The role of chemotherapy in diffuse aggressive lymphomas.
DeVita V, Hubbard S, Young R, Longo D. The role of chemotherapy in diffuse aggressive lymphomas. Seminars In Hematology 1988, 25: 2-10. PMID: 3041598.Peer-Reviewed Original ResearchConceptsDiffuse aggressive lymphomasEarly-stage diseaseCombination chemotherapyAggressive lymphomaDose intensityNew combination chemotherapy programScheduling of drugsDurable complete remissionRole of chemotherapyCombination chemotherapy programsImportant prognostic factorEnd of treatmentComplete remissionStage diseaseChemotherapy programPrognostic factorsSubsequent radiotherapyRisk factorsPrimary treatmentAdditional drugsChemotherapyOld drugsAdvanced stageLymphomaRadiotherapy
1985
Current Management of Hodgkin’s Disease
Behrens B, Young R, DeVita V. Current Management of Hodgkin’s Disease. Drugs 1985, 30: 355-367. PMID: 3905335, DOI: 10.2165/00003495-198530040-00004.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's diseaseDurable complete remissionAcute side effectsCombination chemotherapy programsLong-term complicationsPrognosis of patientsImproved treatment approachesProbable cureInduction therapySalvage therapyMost patientsTerm complicationsChemotherapy programSuch patientsStandard radiotherapySpecific therapySide effectsTreatment approachesPatientsCurrent managementCurrent trialDiseaseTherapyRemission
1976
Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Schein P, DeVita V, Hubbard S, Chabner B, Canellos G, Berard C, Young R. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Annals Of Internal Medicine 1976, 85: 417-22. PMID: 61732, DOI: 10.7326/0003-4819-85-4-417.Peer-Reviewed Original ResearchConceptsHistiocytic lymphomaAdvanced diffuse histiocytic lymphomaExtended disease-free survivalMixed histiocytic-lymphocytic lymphomaNew combination chemotherapy programHistiocytic-lymphocytic lymphomaPrednisone combination chemotherapyCompletion of therapyDiscontinuation of treatmentCombination chemotherapy programsDisease-free survivalDiffuse histiocytic lymphomaBone marrow functionMyelosuppressive phaseComplete remissionMedian durationChemotherapy programCombination chemotherapyComplete responseMarrow functionTumor recurrenceTreatment cyclesFatal diseasePatientsLymphoma
1972
Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy
Canellos G, Young R, DeVita V. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clinical Pharmacology & Therapeutics 1972, 13: 750-754. PMID: 5053816, DOI: 10.1002/cpt1972135part1750.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombination chemotherapyProlonged disease-free intervalExtensive radiation therapyAdvanced Hodgkin's diseaseDisease-free intervalEnd of radiotherapyOnset of chemotherapyCombination chemotherapy programsDegree of myelosuppressionExtensive radiotherapyIntensive radiotherapyCurative intentComplete remissionExtensive diseasePrevious radiotherapyRemission rateChemotherapy programRadiation therapyDrug toxicityPatientsRadiotherapyMonthly cyclesChemotherapyDisease